RANI
Rani Therapeutics Holdings, Inc. · Healthcare
Insiders bought $1.3M of Rani Therapeutics Holdings, Inc. in the last 12 months
2 insiders bought on 2 days.
RANI over the last year
Largest buyers, last 12 months
RANI after insider buys
3 months after each buy, from the first price a copier could get.
23 buys since 2021 with 3 months of prices.
Every filing
31 insider filings since 2021, newest first
Talat Imran · Chief Executive Officer
Mir A Imran · Director and 10% owner
Kate Mckinley · Chief Business Officer
South Cone Investments Limited Partnership · 10% owner
Cortes Isidoro Alfonso Quiroga · 10% owner
South Cone Investments Limited Partnership · 10% owner
Talat Imran · CEO
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
Cortes Isidoro Alfonso Quiroga · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
South Cone Investments Limited Partnership · 10% owner
Cortes Isidoro Alfonso Quiroga · 10% owner
Cortes Isidoro Alfonso Quiroga · 10% owner
Mir A Imran · Director
Andrew Farquharson · Director
Moreno Isidoro Quiroga · 10% owner
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.